In this issue:
COVID disruptions impacted CRC diagnosis and management in Australia
COVID-19 vaccination safe in cancer patients but seroconversion is delayed
Third-line anlotinib demonstrates PFS benefit in refractory mCRC
SNPs do not predict susceptibility to oxaliplatin-induced peripheral sensory neuropathy
Removal of oxaliplatin from FOLFIRINOX induction maintenance for pancreatic cancer feasible
MPACA-3: mFOLFIRINOX superior to S-1 for refractory metastatic pancreatic cancer
Adjuvant radiotherapy may improve survival in extrahepatic bile duct cancer
No benefit to the addition of targeted inhibitors to front-line chemotherapy for biliary tract cancer
High-dose lanreotide autogel efficacious for progressive NETs
Medical cannabis for patients with stage 4 cancers
Please login below to download this issue (PDF)